Octreotide
- Generic Name
- Octreotide
- Brand Names
- Bynfezia, Mycapssa, Sandostatin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83150-76-9
- Unique Ingredient Identifier
- RWM8CCW8GP
- Background
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threat...
- Indication
Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide an...
- Associated Conditions
- Acromegaly, Diarrhea, Metastatic Carcinoid Tumors
- Associated Therapies
- Long-term maintenance therapy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.